Pediatric fever of uncertain source - Revision history

Ostermayer: Convert 29-60 Days flowchart image to table format matching other sections; keep image as thumbnail

2026-04-13T02:45:35Z

Convert 29-60 Days flowchart image to table format matching other sections; keep image as thumbnail

@@ Line 236: / Line 236: @@
 ===29-60 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
 *For toxic infants, treat for sepsis and admit
-*For well-appearing infants, see below algorithm
+*For well-appearing infants:
 [[File:Peds fever 29-60 (2.0).PNG]]
 ===60 Days - 36 Months<ref>Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref>===

Ostermayer: /* 22-28 DaysEvaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 */

2026-04-13T02:39:21Z

22-28 DaysEvaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228

@@ Line 140: / Line 140: @@
 ===22-28 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
 *For toxic infants, treat for sepsis and admit
-*For well-appearing infants, see below algorithm
+*For well-appearing infants:
-[[File:Peds fever 22-28 days (2.0).PNG]]
+[[File:Peds fever 22-28 days (2.0).PNG|22-28 day algorithm]]
 ===29-60 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===

Ostermayer: /* 8-21 DaysEvaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 */

2026-04-13T02:23:10Z

8-21 DaysEvaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228

@@ Line 76: / Line 76: @@
 ===8-21 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
 *For toxic infants, treat for sepsis and admit
-*For well-appearing infants, see below algorithm
+*For well-appearing infants:
-[[File:Peds fever 8-21 days (2.0).png|8-21 day algorithm]]
+[[File:Peds fever 8-21 days (2.0).png|thumb|8-21 day algorithm]]
 ===22-28 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===

Rossdonaldson1: /* Background */

2025-11-05T18:43:14Z

Background

← Older revision		Revision as of 18:43, 5 November 2025
Line 2:		Line 2:
	*Fever accounts for 30% of pediatric visits		*Fever accounts for 30% of pediatric visits
	*Children <3 months are immunocompromised (e.g. poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency)		*Children <3 months are immunocompromised (e.g. poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency)
			*Concern is for missing a serious bacterial infection (SBI)

	===Epidemiology and Risk===		===Epidemiology and Risk===

Ostermayer: /* Initial Empiric Antibiotics for Well-Appearing Infants */

2025-07-05T22:40:49Z

Initial Empiric Antibiotics for Well-Appearing Infants

@@ Line 160: / Line 160: @@
 ==Additional Management==
 ===Initial Empiric Antibiotics for Well-Appearing Infants===
-''source''<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>
+{{Infant fever well antibiotics}}
 {{Acetaminophen pediatric dosing chart}}

Ostermayer: /* Additional Management */

2025-07-05T22:32:13Z

Additional Management

← Older revision		Revision as of 22:32, 5 July 2025
Line 159:		Line 159:

	==Additional Management==		==Additional Management==
	===Initial Empiric Antibiotics for Well-Appearing Infants		===Initial Empiric Antibiotics for Well-Appearing Infants===
	''source''<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>~~===~~		''source''<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|'''Suspected Infection Source'''		\| align="center" style="background:#f0f0f0;"\|'''Suspected Infection Source'''

Ostermayer: /* Additional Management */

2025-07-05T22:31:25Z

Additional Management

← Older revision		Revision as of 22:31, 5 July 2025
Line 159:		Line 159:

	==Additional Management==		==Additional Management==
	===Initial Empiric Antibiotics for Well-Appearing Infants<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===		===Initial Empiric Antibiotics for Well-Appearing Infants
			''source''<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|'''Suspected Infection Source'''		\| align="center" style="background:#f0f0f0;"\|'''Suspected Infection Source'''

Rossdonaldson1: /* See Also */

2023-03-15T16:46:40Z

SMReel: /* Low Risk Lab Criteria */

2022-09-21T15:11:04Z

Low Risk Lab Criteria

← Older revision		Revision as of 15:11, 21 September 2022
Line 143:		Line 143:
	*WBC 5-15 /mm<sup>3</sup>		*WBC 5-15 /mm<sup>3</sup>
	*Absolute Band count <1500 /mm<sup>3</sup>		*Absolute Band count <1500 /mm<sup>3</sup>
			*Procalcitonin ≤0.5 ng/mL
			*ANC ≤4000/mm<sup>3</sup>
	===Urinalysis===		===Urinalysis===
	*Clear		*Clear

SMReel: /* CSF */

2022-09-21T14:49:44Z

CSF

← Older revision		Revision as of 14:49, 21 September 2022
Line 148:		Line 148:
	*WBC <10/high powered field		*WBC <10/high powered field
	===CSF===		===CSF===
			*Studies should include WBC, protein, glucose, Gram stain, and culture for bacteria. Consider viral studies (HSV).
	====0-28 days====		====0-28 days====
	*WBC: 0-22/mm<sup>3</sup>		*WBC: 0-22/mm<sup>3</sup>

← Older revision		Revision as of 16:46, 15 March 2023
Line 211:		Line 211:
	*[[Meningitis (peds)]]		*[[Meningitis (peds)]]
	*[[Febrile seizure]]		*[[Febrile seizure]]
			*[[PECARN Febrile Infant]]

	==External Links==		==External Links==